TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05016609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick HCV Antibody test (OraSure Technologies, Inc)
Description: The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick HCV Antibody test (OraSure Technologies, Inc)
Description: The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick HCV Antibody test (OraSure Technologies, Inc)
Description: The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
Description: Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (Gilead)
Description: Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
Study: NCT05027620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor-cognitive exercise therapy in the home
Description: Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period.
Study: NCT04701203

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Study: NCT04880837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend educational session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive handouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04806906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
Study: NCT05108402

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Phenotyping
Description: After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phenotyping
Description: After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drug intake
Description: After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drug intake
Description: After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet.
Study: NCT05588414

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardization of the sentinel node detection procedure
Description: All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
Study: NCT05461196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPMRx
Description: Patients use a mobile application to track pain medication usage and pain scores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPMRx
Description: Patients use a mobile application to track pain medication usage and pain scores.
Study: NCT05795322

Intervention type: OTHER
Intervention: Sound healing with tuning forks
Description: Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played.
Study: NCT06034782

Intervention type: DIAGNOSTIC_TEST
Intervention: Fine Needle Aspiration
Description: Fine Needle Aspiration of a salivary gland tumor

Intervention type: PROCEDURE
Intervention: Histologic Examination
Description: Histologic examination of resected salivary tumor
Study: NCT04854226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Macronutrients_CARB
Description: Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient_FAT
Description: Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
Study: NCT05220293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Nasal Cream 0.0644%
Description: Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe and applicator device
Description: Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
Study: NCT05289999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset for first injection
Description: Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset for second injection
Description: Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
Study: NCT05818176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIRFA® Navigation System
Description: radiofrequency ablation by NAVIRFA® Navigation System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: radiofrequency ablation by ultrasound
Study: NCT06118853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga or gentle massage plus standard treatment for HSCT
Description: The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
Study: NCT05649046

Intervention type: DEVICE
Group type: OTHER
Intervention: thoracic scan Low dose
Description: within 3 months after the V0 visit
Study: NCT06162533

Intervention type: BIOLOGICAL
Intervention: Vaccination against SARS-CoV-2
Description: Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2

Intervention type: BIOLOGICAL
Intervention: Vaccination against SARS-CoV-2
Description: Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
Study: NCT05734274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Negative control
Description: Sugar-free negative control lozenges.
Study: NCT05649046

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BLOOD SAMPLE
Description: within 3 months after the V0 visit

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FECES SAMPLE
Description: within 3 months after the V0 visit
Study: NCT05136612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiothrapy
Description: Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiothrapy
Description: Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic rehabilitation
Description: The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
Study: NCT05024357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Take Dasatinib orally for 1 year or 6 months post-HSCT.
Study: NCT04816305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMSc
Description: In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMSc
Description: In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofunctional physiotherapy
Description: All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofunctional physiotherapy
Description: All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofunctional physiotherapy
Description: All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
Study: NCT06026137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eFisioTrack Group
Description: Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excercises Group
Description: Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
Study: NCT06160362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 and 20 cells
Description: Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
Study: NCT04775485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
Study: NCT06108843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Arm Pull and Active Release Technique
Description: Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofacial Arm Pull
Description: Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
Study: NCT04721522

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling & ultrasound
Description: Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow
Study: NCT05304429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional counseling
Description: nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
Study: NCT04973462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment COVID-19 + Triazavirin
Description: to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment COVID-19 + Triazavirin
Description: to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
Study: NCT06385535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT)
Description: Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
Study: NCT05069207

Intervention type: OTHER
Intervention: POWER breathe K5
Description: Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate

Intervention type: OTHER
Intervention: POWER breathe K5
Description: Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate

Intervention type: OTHER
Intervention: POWER breathe K5
Description: Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate

Intervention type: OTHER
Intervention: POWER breathe K5
Description: Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
Study: NCT05390944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(20mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(20mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(10mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(10mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT04565431

Intervention type: DRUG
Intervention: Tysabri
Description: Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
Study: NCT04816305

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS sham
Description: During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
Study: NCT04592926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuro SpineNav3D
Description: The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
Study: NCT05178966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bp OneDay psychoeducation program
Description: The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour.